2'allene-substituted nucleoside derivatives

A compound represented by Formula (I):

• or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, wherein:
• R1 at each occurrence is independently selected from the group consisting of:
• 1) hydrogen;
• 2) —CN;
• 3) halogen;
• 4) —N3;
• and
• 5) Substituted or unsubstituted —C1-C8 alkyl;
• R2a, R2b and R2c at each occurrence are independently selected from the group consisting of:
• hydrogen, halogen, and substituted or unsubstituted —C1-C8 alkyl;
• R2 at each occurrence is selected from the group consisting of:
• 1) halogen;
• 2) —CN;
• 3) —N3;
• and
• 4) OR6;
• where R6 selected from the group consisting of:
• hydrogen, hydroxy protecting group, —C(O)RD, —C(O)OR7, and —C(O)NR8aR8b;
• wherein R7 at each occurrence is independently selected from the group consisting of:
• substituted or unsubstituted —C1-C8 alkyl, substituted or unsubstituted —C2-C8 alkenyl, substituted or unsubstituted —C2-C8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclic;
• R8a;
• and R8b at each occurrence is independently selected from the group consisting of:
• hydrogen and R7;
• or alternatively R8a and R8b taken together with the nitrogen atom to which they are attached form a heterocyclic ring;
• R3 is R6;
• or alternatively R2 is —OR6 and R3 and R6 taken together form a group selected from:
• —C(Me)2-, —C(CH2)4—, —CH(Ph)-, —CH(OMe)- and —P(O)(OH)—;
• B at each occurrence is each independently selected from a group consisting of:
• substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclic;
• preferably a heterocycle containing at least one nitrogen;
• R5 is at each occurrence is each independently selected from a group consisting of:
• 1) hydrogen;
• 2) R6;
• 3) —P(O)(OR7a)(OR7b);
• wherein R7a and R7b are each independently selected from the group consisting of a) hydrogen;
• b) unsubstituted or substituted —C1-C8 alkyl;
• 4) —P(O)(OR7a)—O—P(O)(OR7b)(OR7c);
• wherein R7a and R7b are previously defined;
• R7 is selected from the group consisting of a) hydrogen;
• b) unsubstituted or substituted —C1-C8 alkyl;
• and
• 5) —P(O)(OR7a)—O—P(O)(OR7b)—O—P(O)(OR7c)(OR7d);
• wherein R7a, R7b and R7c are previously defined;
• R7d is selected from the group consisting of a) hydrogen;
• b) unsubstituted or substituted —C1-C8 alkyl;
• where X is O or S;
• R9 is R7 wherein R7 is previously defined;
• R10, R11 and R12 are each independently selected from the group consisting of:
• a) hydrogen;
• b) unsubstituted or substituted —C1-C8 alkyl;
• c) R11 is hydrogen, R12 and R10 taken together with the nitrogen which R10 is attached to form a heterocyclic ring;
• d) R11 and R12 taken together with the carbon which they are attached form a ring;
• R13 is hydrogen or R7, wherein R7 is previously defined;
• where X is O or S;
• n is 1-4;
• R8a and R8b are as previously defined;
• R14 is hydrogen or —(CO)—R7, wherein R7 is as previously defined;
• or, R5 and R3 taken together to form
• where X is O or S;
• R6 is as previously defined.